Sunesis Pharmaceuticals (FRA:RYIS) Scaled Net Operating Assets : -0.01 (As of Dec. 2020)

View and export this data going back to 2007. Start your Free Trial

What is Sunesis Pharmaceuticals Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Sunesis Pharmaceuticals's operating assets for the quarter that ended in Dec. 2020 was €2.33 Mil. Sunesis Pharmaceuticals's operating liabilities for the quarter that ended in Dec. 2020 was €2.50 Mil. Sunesis Pharmaceuticals's Total Assets for the quarter that ended in Sep. 2020 was €23.80 Mil. Therefore, Sunesis Pharmaceuticals's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2020 was -0.01.

Sunesis Pharmaceuticals Scaled Net Operating Assets Historical Data

The historical data trend for Sunesis Pharmaceuticals's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunesis Pharmaceuticals Scaled Net Operating Assets Chart

Sunesis Pharmaceuticals Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Scaled Net Operating Assets

Get a 7-Day Free Trial

-0.16

-0.06

-0.07

0.31

-0.01

Sunesis Pharmaceuticals Quarterly Data
	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
Scaled Net Operating Assets	Get a 7-Day Free Trial															0.11	0.13	0.14	-0.04	-0.01

Competitive Comparison of Sunesis Pharmaceuticals's Scaled Net Operating Assets

For the Biotechnology subindustry, Sunesis Pharmaceuticals's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sunesis Pharmaceuticals's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sunesis Pharmaceuticals's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Sunesis Pharmaceuticals's Scaled Net Operating Assets falls into.

Sunesis Pharmaceuticals Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Sunesis Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2020 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2020 )
=	(Operating Assets (A: Dec. 2020 )	-	Operating Liabilities (A: Dec. 2020 ))	/	Total Assets (A: Dec. 2019 )
=	(2.332	-	2.497)	/	33.516
=	-0.00

where

	Operating Assets		(A: Dec. 2020 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	19.109	-	16.777
=	2.332

	Operating Liabilities		(A: Dec. 2020 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	2.721	-	0	-	0.224
=	2.497

Sunesis Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2020 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Dec. 2020 )
=	(Operating Assets (Q: Dec. 2020 )	-	Operating Liabilities (Q: Dec. 2020 ))	/	Total Assets (Q: Sep. 2020 )
=	(2.332	-	2.497)	/	23.8
=	-0.01

where

	Operating Assets		(Q: Dec. 2020 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	19.109	-	16.777
=	2.332

	Operating Liabilities		(Q: Dec. 2020 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	2.721	-	0	-	0.224
=	2.497

Sunesis Pharmaceuticals Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Sunesis Pharmaceuticals's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Sunesis Pharmaceuticals (FRA:RYIS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunesis Pharmaceuticals Inc (FRA:RYIS) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

395 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080

Website

http://www.sunesis.com

Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements.

Sunesis Pharmaceuticals (FRA:RYIS) Headlines

No Headlines